NCT03358134View on ClinicalTrials.gov

Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

October 31, 2017

Conditions
Spondylarthropathies
Interventions
DRUG

Secukinumab

anti IL17 therapy (subcutaneous)

Trial Locations (1)

1105AZ

Academic Medical Center Amsterdam, Amsterdam

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT03358134 - Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis | Biotech Hunter | Biotech Hunter